PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

被引：207

作者：

King, David ^{[1
]}

Yeomanson, Daniel ^{[2
]}

Bryant, Helen E. ^{[3
]}

机构：

[1] Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England

[2] Sheffield Childrens Hosp, Dept Pediat Oncol, Sheffield S10 2TH, S Yorkshire, England

[3] Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Mol Oncol, Sheffield, S Yorkshire, England

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2015年 / 37卷 / 04期

关键词：

neuroblastoma; novel; treatment; PI3K; personalized medicine; PRECLINICAL TESTING PROGRAM; REFRACTORY SOLID TUMORS; GROWTH-FACTOR RECEPTOR; IN-VIVO; PEDIATRIC-PATIENTS; PHASE-I; MAMMALIAN TARGET; DOWN-REGULATION; MYCN PROTEIN; CELL-LINES;

D O I：

10.1097/MPH.0000000000000329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuroblastoma is the most common extracranial cancer in childhood. High-risk neuroblastoma continues to have a poor prognosis and there is an urgent need to design biologically based therapies that specifically target the pathways responsible for malignant transformation and progression. One such pathway is the PI3K/Akt/mTOR pathway. In this article we outline the evidence for aberrant activation of the PI3K/Akt/mTOR pathway in neuroblastoma and discuss the possible mechanisms which mediate it. We also discuss the development of treatments targeting this pathway in neuroblastoma and the challenges that must be overcome before such treatments can enter routine clinical practice.

引用

页码：245 / 251

页数：7

共 54 条

[21] Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program [J].

Houghton, Peter J. ;

Morton, Christopher L. ;

Kolb, E. Anders ;

Gorlick, Richard ;

Lock, Richard ;

Carol, Hernan ;

Reynolds, C. Patrick ;

Maris, John M. ;

Keir, Stephen T. ;

Billups, Catherine A. ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (04) :799-805

[22]

Izycka-Swieszewska E, 2010, POL J PATHOL, V61, P192

[23] Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo [J].

Johnsen, J. I. ;

Segerstrom, L. ;

Orrego, A. ;

Elfman, L. ;

Henriksson, M. ;

Kagedal, B. ;

Eksborg, S. ;

Sveinbjornsson, B. ;

Kogner, P. .

ONCOGENE, 2008, 27 (20) :2910-2922

[24] N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma [J].

Kang, J. ;

Rychahou, P. G. ;

Ishola, T. A. ;

Mourot, J. M. ;

Evers, B. M. ;

Chung, D. H. .

ONCOGENE, 2008, 27 (28) :3999-4007

[25] Insulin-like growth factor-I signaling in human neuroblastoma cells [J].

Kim, B ;

van Golen, CM ;

Feldman, EL .

ONCOGENE, 2004, 23 (01) :130-141

[26] Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program [J].

Kolb, E. Anders ;

Gorlick, Richard ;

Houghton, Peter J. ;

Morton, Christopher L. ;

Lock, Richard ;

Carol, Hernan ;

Reynolds, C. Patrick ;

Maris, John M. ;

Keir, Stephen T. ;

Billups, Catherine A. ;

Smith, Malcolm A. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (06) :1190-1197

[27] Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors [J].

Kurmasheva, Raushan T. ;

Harwood, Franklin C. ;

Houghton, Peter J. .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (05) :1620-1628

[28] In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine [J].

Li, Zhijie ;

Tan, Fei ;

Liewehr, David J. ;

Steinberg, Seth M. ;

Thiele, Carol J. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (11) :758-770

[29] Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrκB rescue of neuroblastoma cells from chemotherapy-induced cell death [J].

Li, ZJ ;

Jaboin, J ;

Dennis, PA ;

Thiele, CJ .

CANCER RESEARCH, 2005, 65 (06) :2070-2075

[30]

Liu XD, 1998, CANCER RES, V58, P5432

← 1 2 3 4 5 6 →